
Medicus Pharma files FDA registration study for SkinJect targeting Gorlin syndrome
Medicus Pharma has filed a registration study with the FDA for its SkinJect treatment aimed at Gorlin syndrome, a rare disorder causing multiple basal cell lesions. This step could lead to commercialization if positive results support a New Drug Appl...

